CartiHeal’s Agili-C implant study aims to demonstrate the superiority of the Agili-C implant over the surgical standard of care for the treatment of cartilage or osteochondral defects. Credit: Dr Manuel González Reyes / Pixabay.

Israel-based CartiHeal has received breakthrough device designation from the Food and Drug Administration (FDA) for its Agili-C implant.

Agili-C is an implant for the treatment of cartilage lesions in arthritic and non-arthritic joints.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The FDA has launched its breakthrough device programme for medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

It is intended to help patients receive more timely access to such medical devices by accelerating their development, assessment and review by the agency.

CartiHeal founder and CEO Nir Altschuler said: “We are extremely pleased that FDA granted the Agili-C implant breakthrough device designation.

“We look forward to working closely with FDA to expedite Agili-C’s review process, once the final IDE study results will be available in order to provide a promising treatment for millions of patients who suffer from cartilage defects and currently lack good treatment options.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A pivotal IDE clinical study is being conducted by CartiHeal to assess the superiority of Agili-C implant over the microfracture and debridement, which are the existing surgical standard of care.

The study has enrolled 251 subjects in 26 sites in the US, Europe and Israel. The subjects include patients with both mild to moderate osteoarthritis and focal defects without arthritic changes.

Final study results are expected next year.

In July, American orthobiologics company Bioventus invested $15m in CartiHeal.

As part of the financing round, the companies agreed on an option structure, under which Bioventus will acquire CartiHeal if the company secures the FDA approval for the Agili-C implant.